Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Out-patients with active rheumatoid arthritis (RA), according to the ACR 1987 revised criteria, with low to moderate disease activity (DAS28-ESR ≥ 2.6 and ≤ 5.1)~2. Patients must be on stable doses of methotrexate (MTX) ≥ 7.5 and ≤ 25 mg/week for at least 12 weeks before the first injection, with appropriate folic acid supplementation~3. Age ≥ 18 years at Screening~4. Body weight at least 50 kg at Screening; BMI: ≥ 18.0 and ≤ 30.0 kg/m2 at Screening~5. Negative tuberculosis test at Screening~6. Heterosexually active male and female patients of childbearing potential are obliged to follow whatever contraceptive and / or breastfeeding restrictions may be required for their concomitant medication(s), including methotrexate.~In addition, heterosexually active male and female patients of childbearing potential are required to use effective double-method contraception (one hormonal contraceptive or intrauterine device and one other additional contraceptive method) for 1 month before the first administration of the IMP, during the course of the trial, and for 6 month after the last injection of MT203.~No special requirements are made for female patients proven to be post-menopausal (at least 2 years after last menstrual period and FSH ≥ 40IU/L), surgically sterilized or hysterectomized. Likewise no special requirements for heterosexually active male who are surgical sterilized.~Pregnant or lactating female patients have to be excluded.~Exclusion Criteria:~1. Participation in another clinical trial or previous dosing in this trial~2. Use of specified medications within certain timeframes or use of certain comedications~3. History or presence of specified diseases~4. Drug abuse~5. Certain laboratory parameters outside a specified range~6. Donation of blood~7. Relevant decrease in lung function~8. Infections, frequent or chronic infections, herpes zoster~9. Females: positive pregnancy test~10. Presence of history of tuberculosis~11. History of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Namilumab 150 mg (Type: EXPERIMENTAL): Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
- Namilumab 300 mg (Type: EXPERIMENTAL): Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
- Placebo (Type: PLACEBO_COMPARATOR): Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).